Bromantane

A Russian-developed "actoprotector" — a compound claimed to enhance physical and mental resilience without classical stimulant effects. Acts partly by upregulating dopamine synthesis enzymes rather than blocking reuptake.

Bromantane is a Russian compound classed as an actoprotector — a term with no Western equivalent, meaning something intended to sustain physical and mental performance under stress. Its mechanism is uncertain and largely preclinical: the Russian product information itself describes increased dopamine release AND reuptake inhibition alongside effects on dopamine synthesis, and the enzyme-expression story that circulates in nootropic forums rests principally on a rat experiment. The popular narrative — slow onset, builds over days, no crash — is user report plus extrapolated mechanism, not established human pharmacokinetics; the monograph reports a half-life around 11 hours with effects beginning within hours.

Nearly all published research is Russian, much of it from the Soviet/post-Soviet sports-science program, with small samples and limited methodology visible in English-language literature. A Russian clinical trial reported benefit in asthenia (fatigue syndromes). Western replication is essentially absent — by the evidence standards this app applies to peptides, bromantane grades as Anecdotal-to-Limited.

• Approved in Russia for asthenia. Related diagnoses have existed in Western classification — WHO's ICD-10 carried neurasthenia — but the Russian trial populations and diagnostic conventions do not map cleanly onto contemporary US practice, which is part of why the evidence does not transfer.
• The clinical evidence is outcome-specific: a 180-participant Russian multicenter trial supports LIMITED benefit for asthenia symptoms. For the healthy-person cognitive, athletic or resilience enhancement it is actually bought for: None shown. It has not been independently replicated outside that research community.
• No Western randomised controlled trial exists.
• Prohibited in sport since the pre-WADA era — its doping history is where most Western awareness of it comes from — and currently classified by WADA as a non-specified stimulant.
• The Russian monograph itself lists contraindications the grey market never mentions: pregnancy, lactation, age under 18, and hypersensitivity — with excessive activation, trouble falling asleep, and allergic reactions as its reported adverse effects.

Orally active. Human pharmacokinetics beyond the monograph half-life are poorly characterised, and what is sold in the West is research-chemical supply, so purity is unverified. It is prohibited in tested sport and produces anti-doping violations.

The honest risk statement is that the safety profile is poorly characterized in Western literature — an absence of documented harms in small foreign trials is not evidence of safety. Banned by WADA as a stimulant and masking agent since 1997, which reflects both its use history and detectability concerns.

• Anyone competing in tested sport, where it is prohibited
• Anyone pregnant or breastfeeding
• Anyone with a psychiatric condition, given unclear dopaminergic effects
• Anyone unwilling to accept unverified research-chemical supply

• No characterised interaction profile exists in Western literature.
• Other dopaminergic drugs, on mechanistic grounds.
• Stimulants, where additive effects on sleep and blood pressure would be expected.

• Sleep, since dopaminergic compounds commonly disturb it even when they do not feel stimulating.
• Whether the effect is real or expectation, which is unusually hard to judge with a compound whose claimed effect builds slowly.
• Blood pressure.
• It is prohibited in tested sport, full stop — a violation does not require intent.

The trial evidence includes only about a week of post-treatment observation, which cannot rule out dependence, withdrawal or delayed effects after the longer non-medical use patterns people actually run. The celebrated "no rebound" property is a selling point resting on that same short window. What stopping looks like after months of use has simply never been studied.

US: not approved, not scheduled — sold as a "research chemical" with no quality oversight. WADA-banned in sport. Prescription drug in Russia.

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

• Pilot clinical trial of ladasten
  Eksp Klin Farmakol, 2006
• Ladasten versus placebo effect self-evaluated by neurasthenia patients with different EEG alpha rhythm types
  Eksp Klin Farmakol, 2012
• Ladasten in the management of non-motor symptoms of Parkinson's disease
  Zh Nevrol Psikhiatr Im S S Korsakova, 2011

• Plant Adaptogens-History and Future PerspectivesNutrients · 2021
• Toxic effect of single treatment with bromantane on neurological status of experimental animalsBull Exp Biol Med · 2002
• [Study of heat-protective effects of bromantane at various levels of overheating]Vopr Med Khim · 1995
• [An acute toxicity study of bromantane]Eksp Klin Farmakol · 2000
• [The effect of bromantane on the physical work capacity of laboratory animals]Eksp Klin Farmakol · 1998
• [Analysis of pharmacological properties of bromantane]Biull Eksp Biol Med · 1999
• [A quantitative pharmaco-electroencephalographic analysis of the action of bromantane]Biull Eksp Biol Med · 1993
• [Effect of bromantane on the rat neurologic status in two month course]Eksp Klin Farmakol · 2000
• [The effect of bromantane on the cardiovascular and sympathetic-adrenal systems in animals]Eksp Klin Farmakol · 2000
• [Effects of bromantane and sidnocarb on long-term operant conditioning and its vegetative correlates in rats]Eksp Klin Farmakol · 2000
• [The neuro- and psychophysiological effects of bromantane]Voen Med Zh · 2000
• [The effect of bromantane on the dopamin- and serotoninergic systems of the rat brain]Eksp Klin Farmakol · 1995